Delivery Order SPE2DB20D3103-SPE2DB25FQ5A8
- Not listed
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on September 26, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. This order, valued at $15,173.15 with a firm fixed price contract type, is scheduled for completion by September 29, 2025, and will be fulfilled from the company's Conshohocken, Pennsylvania location. The award was competitively procured with no set-aside designation and represents a delivery order against...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials, with a ceiling value of $8,146.58 and an ultimate completion date of September 29, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a continuation of AmerisourceBergen's pharmaceutical supply services under the Defense Logistics Agency's Medical Supply Chain...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on September 18, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials, with a ceiling value of $1,116.63. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was competitively procured. The contract is scheduled for completion by September 19, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- AmerisourceBergen Drug Corp has been awarded a delivery order valued at $5,639.94 by the Defense Logistics Agency (DLA) for the supply of Ozempic 1 mg/dose (4 mg/3 ml) in 3 ml vials. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of August 27, 2025, awarded on August 26, 2025. The pharmaceutical products will be delivered to Conshohocken, Pennsylvania, and this award was made through open competition without a set-aside designation. This delivery...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on September 5, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml vials, with a contract ceiling value of $5,708.57 and an ultimate completion date of September 8, 2025. This is a firm fixed-price delivery order with no set-aside designation, awarded through open competition. The place of performance is the company's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) 3 mL vials with a ceiling value of $42,114.61. This competitively awarded, firm fixed-price delivery order is non-set-aside and carries an ultimate completion date of August 4, 2025, with performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a continuation of AmerisourceBergen's role as a critical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3ml vials, with a contract ceiling value of $7,306.02 and an ultimate completion date of August 29, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a pharmaceutical supply requirement from the federal government. The award is performed at AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $3,633.25 to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials. The contract utilizes a firm fixed price arrangement with an ultimate completion date of August 8, 2025, and carries no set-aside designation, indicating it was competitively awarded. Performance will occur at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials, with a ceiling value of $37,730.25. This competitively awarded, firm fixed-price delivery order is set to be completed by August 20, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement supporting federal medical supply...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 26, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) in 3 ml vials, with a contract ceiling value of $49,655.94. This is a firm fixed-price delivery order issued under a competitive procurement with no set-aside designation. The award reflects AmerisourceBergen's role as a critical pharmaceutical distributor supporting federal medical supply chains, with performance to take place at the company's...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FQ5A8Delivery Order
AmerisourceBergen Drug Corp was awarded a delivery order on September 27, 2025, by the Defense Logistics Agency (DLA) for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials, with a contract ceiling value of $4,699.95 and an ultimate completion date of September 29, 2025. The contract is structured as a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is listed as Conshohocken, Pennsylvania, which is also the headquarters location of AmerisourceBergen Drug Corp. This delivery order represents a continuation of AmerisourceBergen's extensive relationship with the DLA Medical Supply Chain. The award is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This prime contract vehicle enables AmerisourceBergen to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally, including medications, vaccines, and medical devices across multiple therapeutic categories. The company's federal contracting history demonstrates consistent capability in fulfilling competitive pharmaceutical procurement requirements for the Department of Defense healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.7k | 9/27/25 |